Across the long human struggle with cancer, one of the quieter discoveries of recent years is that the mind may not stay outside the body's defenses. A team at West China Hospital of Stomatology in Sichuan has traced how chronic stress, the weight of persistent anxiety and low mood, can travel from the brain through the pituitary and into the bone marrow, where it reshapes the immune cells that should be guarding the mouth against oral squamous cell carcinoma. Their work, published in the International Journal of Oral Science, suggests that the emotional burden carried by patients is not merel
Chronic Stress Linked to Faster Oral Cancer via Brain-Bone Marrow-Immune Pathway in New Study
Oral squamous cell carcinoma patients with chronic stress showed worse overall survival and higher risk of progression and postsurgical recurrence.
Chronic stress as an active biological driver of oral cancer
Mark
Start with the basic claim. What is new here?
Mimi
Stress has been tied to cancer before, but the route was murky. This study maps one: hypothalamus, pituitary, then bone marrow, with the hormone α-MSH raising suppressive immune cells that blunt CD8+ T cells.
Mark
And the human evidence?
Mimi
UK Biobank linked anxiety and depression to higher head and neck cancer mortality, and α-MSH and LOX-1 rose from normal mucosa to leukoplakia to OSCC.
Luke
Careful, though. The Biobank stress measure was a single time point. The authors themselves say causality can't be established.
Mimi
Right. The causal chain is shown in mice, not in people.
Luke
So the mechanism is mouse data, and the human data is correlation.
Mark
What about the drug result?
Mimi
Combining the MCSR inhibitor JNJ-10229570 with anti-PD-1 gave the smallest tumors and most CD8+ T cell infiltration, without overt toxicity.
Luke
In mice. Whether it helps patients is unknown, and dosing and predictive biomarkers haven't been worked out.
Mark
Any practical takeaway now?
Mimi
Only as proposals: α-MSH and LOX-1 as biomarkers, and screening for anxiety and depression to guide follow-up. Those still need testing.
O Pulso
- Chronic stress appears to quietly feed oral cancer, pushing a brain-to-bone-marrow signal that multiplies immune cells working against the body's own defenses.
- Patients who carry anxiety or depression show worse survival and a higher chance of the tumor returning after surgery, raising the stakes of an often-overlooked emotional burden.
- Researchers have found that blocking the stress-linked melanocortin receptor in mice, alongside anti-PD-1 therapy, shrank tumors and restored T cell activity without visible toxicity.
- The findings remain at the mouse-and-observation stage, with causality unproven in people and clinical validation still ahead before anything reaches the patient bedside.
Across the long human struggle with cancer, one of the quieter discoveries of recent years is that the mind may not stay outside the body's defenses. A team at West China Hospital of Stomatology in Sichuan has traced how chronic stress, the weight of persistent anxiety and low mood, can travel from the brain through the pituitary and into the bone marrow, where it reshapes the immune cells that should be guarding the mouth against oral squamous cell carcinoma. Their work, published in the International Journal of Oral Science, suggests that the emotional burden carried by patients is not merely a companion to disease but a biological participant in it. It also offers a tentative path forward, in which calming this stress-driven signal might help unlock treatments that have so far worked poorly against this cancer.
At West China Hospital of Stomatology in Sichuan, a research team set out to answer a question that has lingered in oncology for years: how does a stressed mind actually reach a tumor? Chronic anxiety and depression had been linked to cancer progression, but the route the signal took from brain to immune system remained hidden. The researchers looked across large population data, patient tissue samples and laboratory mice to follow that path.
In the UK Biobank records, people living with anxiety or depression faced higher mortality from head and neck squamous cell cancers, and chronically stressed patients fared worse overall. In patient samples, two markers rose together as tissue moved from healthy mucosa to precancerous lesions and then to full oral cancer: a hormone called α-MSH and a marker of immune cells that suppress the body's attack on tumors. The mouse experiments then showed the sequence. Prolonged restraint stress activated a region of the brain, which prompted the pituitary to release more of the hormone, and this in turn expanded suppressive immune cells in the bone marrow. Cancer-fighting T cells were pushed aside, tumors grew faster, and recurrence after surgery became more likely.
The team also found that blocking the melanocortin receptor could reverse much of this damage. When the blocker was paired with an anti-PD-1 immunotherapy, which often struggles against oral cancer, the mice developed the smallest tumors and the richest T cell presence, with no overt toxicity and less of the weight loss that usually accompanies that treatment.
The authors are careful about what remains unknown. Their population data captured stress at a single moment, so cause cannot yet be fully proven, and the pathway must still be confirmed in patients. Their next steps include refining dosing, finding biomarkers that predict risk and testing combinations in clinical trials. If those steps succeed, a simple blood test and a routine question about anxiety might one day help clinicians recognize who needs closer watch, and who might be helped by easing the stress that is quietly working inside the disease.
Researchers at West China Hospital of Stomatology, Sichuan University, have published a study in the International Journal of Oral Science (DOI: 10.1038/s41368-026-00468-x) tracing a path from a stressed brain to a faster-growing oral cancer. The team reports that chronic stress accelerates oral squamous cell carcinoma, or OSCC, by switching on what they call the hypothalamic–pituitary–bone marrow axis and reshaping the immune environment around the tumor.
The question behind the work is an old one. Chronic psychological stress, usually showing up as anxiety or depression, has increasingly been recognized as a factor in how tumors start and progress, touching both endocrine and immune function. What has stayed unclear is how the central nervous system actually carries that signal to the immune system. The team drew on several sources to look for an answer: the UK Biobank cohort, serum and tissue samples from patients, and mouse models covering chemical carcinogenesis, orthotopic tongue tumors and recurrence after surgery.
In the UK Biobank data, anxiety and depression were each independently associated with higher mortality from head and neck squamous cell carcinoma, and chronically stressed patients had significantly worse overall survival. In patient samples, levels of two markers climbed in step as tissue moved from normal mucosa to oral leukoplakia to OSCC. One was serum α-melanocyte-stimulating hormone (α-MSH). The other was LOX-1, a marker of human polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), immune cells that dampen the body's attack on tumors. The two were strongly correlated with each other.
The mouse experiments laid out the mechanism step by step. Chronic restraint stress activated neurons in the hypothalamic paraventricular nucleus and increased production of proopiomelanocortin (POMC) in the intermediate lobe of the pituitary. Serum α-MSH rose, PMN-MDSCs expanded in the bone marrow, CD8+ T cells were suppressed, and tumors grew faster. Stress also worsened recurrence after surgery. RNA sequencing pointed to a chemokine called CXCL13 as a key stress-induced signal; neutralizing it reduced PMN-MDSC accumulation, restored CD8+ T cell infiltration and slowed tumor growth.
Tissue microarrays from patients echoed this. LOX-1+ PMN-MDSCs increased with clinical stage, tracked with CD68+CD206+ M2 macrophages, varied inversely with CD8+ T cells, and predicted poorer survival.
The therapeutic finding is the one likely to draw attention. Blocking the melanocortin 1 receptor with an inhibitor, JNJ-10229570, restored antitumor immunity. Paired with anti-PD-1 checkpoint therapy, it produced the smallest tumors and the greatest CD8+ T cell infiltration while suppressing PMN-MDSCs, with no overt toxicity. The blockade was well tolerated and eased the weight loss associated with anti-PD-1 treatment in mice. That matters because response rates to PD-1/PD-L1 blockade in OSCC are low.
The authors frame the results as recasting chronic stress as an active biological driver of oral cancer rather than only a psychological burden. They say the axis appears to be engaged early, even at the precancerous stage. They suggest circulating α-MSH and LOX-1+ PMN-MDSC density could become minimally invasive biomarkers for patients at higher risk of progression or relapse, and that routine screening for anxiety and depressive symptoms might flag people needing closer follow-up.
The authors are explicit about limits. Stress in the UK Biobank was assessed at a single time point, so causality cannot be established, and the pathway still needs validation in patients. Next steps they name are optimizing dosing, identifying predictive biomarkers and testing combinations with other immunomodulators in clinical trials.
Citações Notáveis
Single-time-point stress assessments in the UK Biobank mean causality cannot be established, and further studies are needed to validate the pathway in patients.— Study authors
Quer a matéria completa?
Leia o original em Mirage News ↗